skip to Main Content
Nghiem Lab
  • Research
  • People
  • Publications
  • News
  • Contact
  • Photo Gallery
  • Search
Open Mobile Menu
×Close search
Publications

Merkel Cell Carcinoma: An Unusually Immunogenic Cancer Proves Ripe for Immune Therapy.

Vandeven N, Nghiem P.

J Oncol Pract. 2016 Jul;12(7):649-50.

PMID: 27407162

View on PubMed - View PDF

J Oncol Pract. 2016 Jul;12(7):649-50.
Related Items

One in a hundred million: Merkel cell carcinoma in pediatric and young adult patients is rare but more likely to present at advanced stages based on US registry data.

Travel burden associated with rare cancers: The example of Merkel cell carcinoma.

Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.

  • previous post: PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
  • next post: Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.
© Copyright University of Washington · Paul Nghiem Lab - All Rights Reserved 2019
Updated: Aug 22, 2018 @ 5:39 pm
Back To Top
×